美国 · 平台与数据 · Yahoo Finance

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

来源：Yahoo Finance · 美国 10 小时前

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.

在 Yahoo Finance 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finance.yahoo.com)

推荐阅读

The Motley Fool

Axon Enterprise vs. ServiceNow: Which Industrials Stock Is a Better Buy in 2026?

Tenet Healthcare Q3 Earnings Call Highlights

First Business outlines ~10% annual loan growth and sees NIM staying above 3.60%–3.65% long-term range

Hedge fund Arini sells $800 million in debt as losses mount - WSJ

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

CNBC is at the Fort Lauderdale International Boat Show